Last 12 months
Inside the activity.
2 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 1 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 55,000 shares Expires 2032-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 31,165 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 213,700 Underlying: Common Stock · 31,165 shares Expires 2031-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:05 UTC |
Lurker NancyDirector
|
GiftStock Option (Right to Buy) · Derivative | 31,165 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-25-005229 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,165 shares Expires 2031-02-09 F1 · kind: On July 2, 2025, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:13 UTC |
Duker Jay S.Director · President and CEO
|
OtherCommon Stock | 56,665 | $8.21 | $465,219.65 |
DisclosureSEC source: 0001562180-25-005074 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 986 F1 · kind: The shares were sold by the reporting person to the Duker Family 2024 Irrevocable Trust, or the Family Trust, in exchange for a promissory note in the principal amount of $465,219.65, representing the fair market value as determined by utilizing the average of the high and low per share trading price on the date of the sale. The shares held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 25, 2025 Filed May 27, 2025 20:08 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004193 · primarydocument.xml · derivative · entry 3 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning May 25, 2024. F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning May 25, 2024. Read SEC document |
| May 25, 2025 Filed May 27, 2025 20:08 UTC |
Elston GeorgeChief Financial Officer
|
Tax withholdingCommon Stock | 2,202 | $5.68 | $12,507.36 |
DisclosureSEC source: 0001562180-25-004193 · primarydocument.xml · nonDerivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,848 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| May 25, 2025 Filed May 27, 2025 20:08 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004193 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2025 Filed May 19, 2025 20:06 UTC |
Zaderej Karen L.Director
|
PurchaseCommon Stock | 5,000 | $5.99 | $29,950.00 |
DisclosureSEC source: 0001562180-25-003997 · primarydocument.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,500 Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:06 UTC |
Zaderej Karen L.Director
|
PurchaseCommon Stock | 5,000 | $5.81 | $29,050.00 |
DisclosureSEC source: 0001562180-25-003997 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Read SEC document |
| May 15, 2025 Filed May 15, 2025 20:06 UTC |
Zaderej Karen L.Director
|
PurchaseCommon Stock | 5,000 | $5.47 | $27,350.00 |
DisclosureSEC source: 0001562180-25-003873 · primarydocument.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.48. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:06 UTC |
Zaderej Karen L.Director
|
PurchaseCommon Stock | 5,000 | $5.42 | $27,100.00 |
DisclosureSEC source: 0001562180-25-003873 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.41 to $5.42. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 20:06 UTC |
Duker Jay S.Director · President and CEO
|
OtherCommon Stock | 20,000 | $6.16 | $123,100.00 |
DisclosureSEC source: 0001562180-25-002626 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,651 F1 · kind: The shares were sold by the reporting person to the Duker Family 2024 Irrevocable Trust, or the Family Trust, in exchange for a promissory note in the principal amount of $123,100, representing the fair market value as determined by utilizing the average of the high and low per share trading price on the date of the sale. The shares held in the Family Trust are for the benefit of the reporting person's children. The reporting person's spouse is a trustee of the Family Trust. The reporting person disclaims beneficial ownership of the security and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC |
Lurker NancyDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001134 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three annual installments beginning February 9, 2023. F2 · derivative.expiration_date: The restricted stock units vests in three annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC |
Lurker NancyDirector
|
Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001134 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,834 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001135 · primarydocument.xml · derivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. F2 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 5,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001135 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,150 shares acquired on January 31, 2025 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 7,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001133 · primarydocument.xml · derivative · entry 4 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vests in three annual installments beginning February 9, 2023. F3 · derivative.expiration_date: The restricted stock units vests in three annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 2,055 | $6.50 | $13,347.23 |
DisclosureSEC source: 0001562180-25-001133 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,651 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 23:19 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-001133 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 21:14 UTC |
Sanders Reginald J.Director
|
GrantStock Options (Right to buy) · Derivative | 80,000 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-25-000272 · primarydocument.xml · derivative · entry 1 Sanders Reginald J. · CIK 0002048275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-01-08 F1 · derivative.exercise_date: The option becomes exercisable in three ratable annual installments beginning on January 8, 2026. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:04 UTC |
Lurker NancyDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 75,134 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,133 Underlying: Common Stock · 75,134 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. F3 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:04 UTC |
Lurker NancyDirector
|
Exercise / conversionCommon Stock | 75,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,285 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · derivative · entry 8 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,715 Underlying: Common Stock · 15,285 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. F6 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
Tax withholdingCommon Stock | 4,808 | $8.68 | $41,733.44 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · nonDerivative · entry 4 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,566 F2 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 15,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · nonDerivative · entry 3 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:03 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 20,794 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000226 · primarydocument.xml · derivative · entry 9 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,206 Underlying: Common Stock · 20,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. F6 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:03 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 6,108 | $8.68 | $53,017.44 |
DisclosureSEC source: 0001562180-25-000226 · primarydocument.xml · nonDerivative · entry 4 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,706 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:03 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 20,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000226 · primarydocument.xml · nonDerivative · entry 3 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 16:04 UTC |
Landis John B.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000227 · primarydocument.xml · derivative · entry 3 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested on the one-year anniversary of the grant date. F1 · derivative.expiration_date: Fully vested on the one-year anniversary of the grant date. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 16:04 UTC |
Landis John B.Director
|
Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000227 · primarydocument.xml · nonDerivative · entry 1 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:04 UTC |
Lurker NancyDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 12,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,333 Underlying: Common Stock · 12,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:04 UTC |
Lurker NancyDirector
|
Exercise / conversionCommon Stock | 12,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · derivative · entry 7 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. F5 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
Tax withholdingCommon Stock | 5,267 | $8.26 | $43,505.42 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · nonDerivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,089 F2 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 876 shares acquired on July 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:03 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000226 · primarydocument.xml · derivative · entry 8 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. F5 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:03 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 10,007 | $8.26 | $82,657.82 |
DisclosureSEC source: 0001562180-25-000226 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,020 F1 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 21:03 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000226 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:05 UTC |
Hassan FredDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000235 · primarydocument.xml · derivative · entry 1 Hassan Fred · CIK 0001110744 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:04 UTC |
ANDO GORANDirector
|
GrantStock Option (Right to Buy) · Derivative | 41,500 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000233 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires 2035-01-03 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC |
Ribeiro RamiroChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000230 · primarydocument.xml · derivative · entry 2 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Common Stock · 117,000 shares Expires 2035-01-03 F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC |
Ribeiro RamiroChief Medical Officer
|
GrantRestricted Stock Units · Derivative | 59,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000230 · primarydocument.xml · derivative · entry 1 Ribeiro Ramiro · CIK 0002013623 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026. F1 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:04 UTC |
Landis John B.Director
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000227 · primarydocument.xml · derivative · entry 2 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC |
Lurker NancyDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000228 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · derivative · entry 6 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Common Stock · 117,000 shares Expires 2035-01-03 F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC |
Elston GeorgeChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 59,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000229 · primarydocument.xml · derivative · entry 5 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 59,000 shares Expires not disclosed F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026. F3 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:04 UTC |
DICICCO WENDY FDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000231 · primarydocument.xml · derivative · entry 1 DICICCO WENDY F · CIK 0001225165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:05 UTC |
Zaderej Karen L.Director
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000234 · primarydocument.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC |
Duty StuartDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000232 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:03 UTC |
Duker Jay S.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 390,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000226 · primarydocument.xml · derivative · entry 7 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2035-01-03 F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.